Browse press releases
The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.
- Hengrui Pharma Reports 2026 Interim Results as Innovation and Globalization Continue to Drive Business MomentumHengrui Pharma (“Hengrui” or “the Company”) today announced its financial results for the first half of 2026. During the reporting period, innovative drugs remained the Company’s key growth driver, while globalization initiatives continued to validate the global value of Hengrui’s innovation portfolio. Financial Highlights In the first half of 2026, Hengrui reported revenue of RMB15.46 billion. Drug sales revenue was RMB13.95 billion, representing a year-over-year increase of 1.87%. Innovative drug sales increased by 16.38% year-over-year and accounted for 63.16% of total drug sales, with non-oncology innovative drug sales increasing by 73.97% year-over-year and emerging as an increasingly important growth driver. Net profit attributable to shareholders of the listed company was RMB4.47 billion, up 0.34%. R&D investment totaled RMB4.61 billion, representing 29.8% of revenue. Pipeline and Regulatory Highlights Hengrui continued to advance its pipeline in China during the reporting period, obtaining seven innovation-related approvals, including two Class 1 innovative medicines, one Class 2 innovative medicine and four additional indications. At the end of the reporting period, nine marketing applications had been accepted for review by China’s National Medical Products Administration, while 17 clinical programs had advanced to Phase III, 22 to Phase II, and 10 innovative assets had entered Phase I clinical development. Hengrui also reported progress across its metabolic pipeline. Two Phase III studies of ribupatide injection, a GLP-1/GIP dual receptor agonist, in China for type 2 diabetes reported positive topline results, supporting a planned NDA submission. HRS-7535, an oral small molecule GLP-1 receptor agonist, met all primary and key secondary endpoints at Week 44 in a China Phase III obesity study, with continued weight loss through Week 50 and mean body-weight reduction of up to 11.1%. An NDA submission is planned. Global Partnerships and Business Development Hengrui continued to advance its globalization strategy through diversified collaboration models. Since 2023, the Company has completed 13 overseas business development transactions, including out-licensing, NewCo and strategic alliances, with a total potential transaction value of approximately US$42 billion. These collaborations include leading global pharmaceutical companies such as BMS, GSK and others. Among the diversified collaboration models Hengrui has explored, NewCo has also seen important progress in 2026. Kailera Therapeutics completed its Nasdaq IPO in April 2026, becoming one of the largest biotech IPOs at the time. Braveheart Bio also successfully listed on the Nasdaq Global Market on August 6, 2026. Scientific Recognition During the reporting period, 204 research findings related to Hengrui products were published in academic journals and received international recognition. Hengrui participated in the American Society of Clinical Oncology Annual Meeting for the 16th consecutive year, with 91 studies accepted, including 11 oral presentations—a new high for the Company. Research in non-oncology areas was also presented at major international congresses, including the American Diabetes Association, International Stroke Conference, World Congress of Nephrology, American College of Cardiology, American Academy of Dermatology, and European Alliance of Associations for Rheumatology. Outlook Looking ahead, Hengrui will continue to advance its innovation and globalization strategy, while further pursuing its dual-growth strategy across oncology and chronic diseases. The Company will strengthen its global R&D capabilities, pursue diversified international collaboration models, and continue to focus on delivering sustainable long-term value and bringing more high-quality innovative therapies to patients worldwide.
- Penguin AiPenguin Ai Launches Utilization Management and HCC Risk Adjustment Solutions in AWS MarketplaceAutonomous, explainable AI executes two of the most administratively intensive payer workflows — inside the health plan's own AWS environment. Penguin Ai , a healthcare-native artificial intelligence company, today announced that its Utilization Management and HCC Risk Adjustment solutions are now available in AWS Marketplace , a digital catalog with thousands of software listings from independent s
- OracleOracle Health Expands Clinical AI Agent with Automated Coding, Dictation, and Chart ReviewCompanies: Oracle CorporationOracle Health today announced new capabilities for Oracle Health Clinical AI Agent, now available in the U.S., that expand AI across clinical...
- GajuraRatedByPatients Launches Price Comparison Site for U.S. Telehealth, Medications and PharmaciesRatedByPatients today launched a free comparison site for U.S. telehealth, publishing hand-checked prices for 154 virtual care providers, 78 prescription medications and the mail-order pharmacies that dispense them, in a market where the same drug can cost one patient $4,800 more a year than another.To view an enhanced version of this graphic, please...
- OracleOracle Health Expands Clinical AI Agent with Automated Coding, Dictation, and Chart ReviewCompanies: Oracle CorporationNew AI capabilities help clinicians document faster, streamline professional fee coding, and surface relevant patient context — Oracle Health today announced new capabilities for Oracle Health Clinical AI Agent, now available in the U.S., that...
- OracleOracle Health Expands Clinical AI Agent with Coding, Dictation, and Chart ReviewCompanies: Oracle CorporationAustin, Texas—Aug 19, 2026 Oracle Health today announced new capabilities for Oracle Health Clinical AI Agent, now available in the U.S., that expand AI across clinical documentation, coding, and chart review workflows. The new capabilities automate professional fee coding for ambulatory workflows, enable physicians to dictate directly into clinical documentation, and assist with chart review by surfacing clinically
- Empatica, Inc.Empatica Receives FDA Clearance for Parkinson's MonitoringEmpatica, a leader in digital biomarker development and clinical-grade wearable technology, today announced that the Empatica Health Monitoring Platform for Parkinson's has received 510(k) clearance from the U.S. Food and Drug Administration (FDA)....
- BetterLife Pharma Inc.BetterLife Pharma Appoints Mahan Chehrenama, DO, as Chief Medical OfficerBetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) ("BetterLife" or the "Company"), a biotechnology company developing treatments for neurological disorders, today announced the appointment of Mahan Chehrenama, DO, as Chief Medical Officer. Dr. Chehrenama will lead clinical development for BETR-001, the Company's non-hallucinogenic neuroplastogen advancing toward an Investigational New Drug (IND) application for...
- Cizzle Brands CorporationCizzle Brands Corporation Announces Filing of Form F-10 Registration Statement with the U.S. Securities and Exchange Commission and Intention to List on a U.S. Exchange; Appoints Finance & Governance Veteran Dominic Scarangella to Board of DirectorsTORONTO, August 19, 2026--Cizzle Brands Corporation (Cboe Canada: CZZL; OTCQB: CZZLF; Frankfurt: 8YF) ("Cizzle Brands" or the "Company"), the vertically integrated sports nutrition company that is elevating the game in health and wellness, is pleased to announce two important milestones in support of its continued growth: (i) the filing of a registration statement on Form F-10 (the "Registration Statement") with the United States Securities and Exchange Commission (the "SEC"), together with the
- Norroy Bioscience Co., Ltd.NORROY BIOSCIENCE Granted FDA Breakthrough Therapy and Fast Track Designations for Kidney Cancer Imaging ProductNORROY BIOSCIENCE (NORROY), a clinical-stage biotechnology company focused on innovative targeted radiopharmaceuticals, announced that the U.S. Food and Drug Administration (FDA) has granted both Breakthrough Therapy and Fast Track designations...
- Everest Medicines Reports 1H 2026 Results, Enters New Phase as Growth Accelerates and Innovation Gains MomentumEverest Medicines (01952.HK) announced its interim results for the six months ended June 30, 2026. Everest delivered strong growth and reached an important profitability milestone in the first half of 2026. Total revenue increased 157% year-on-year to RMB 1.148 billion, driven by continued commercial momentum across the company’s portfolio. Gross margin excluding non-cash items reached 73.7%, while operating expenses as a percentage of revenue decreased by 64.0 percentage points year-on-year, reflecting increasing operating leverage and execution efficiency. From the first-half results, the company’s growth drivers are broadening beyond the commercialization of core products to include portfolio expansion, monetization of innovative assets, and global expansion. In the first half of 2026, the company achieved non-IFRS net profit of RMB 97.23 million, while IFRS net loss narrowed by 98% year-on-year. Everest ended the period with RMB 1.859 billion in cash. Following the reporting period, the company received approximately RMB 770 million in July from the upfront payment under its global licensing and collaboration agreement for civorebrutinib, further strengthening its financial position and capacity to invest in future growth. Mr. Yifang Wu, Chairman of the Board of Everest Medicines, said: “Everest Medicines has entered a new phase of development as an innovation-driven, integrated biopharmaceutical company. Guided by our 2030 Strategy, we are strengthening our capabilities in innovation, commercialization, and global development, accelerating the realization of global value and laying a stronger foundation for sustainable, high-quality growth.” During the period, the company achieved profitability, while expanding its innovative pipeline and advancing its R&D programs. Through continued efforts to strengthen its BD capabilities, the company is developing a model that combines in-licensed and internally developed early-stage assets, exemplified by civorebrutinib (also known as EVER001), with internal incubation and development creating opportunities to out-license innovative assets and realize their value. At the same time, the company is bringing in high-quality mid- to late-stage assets, exemplified by NEFECON(R), while continuing to build its commercialization capabilities and generate further opportunities for BD partnerships. These efforts are enhancing the efficiency of innovation resource allocation and accelerating the translation of innovation into clinical and commercial value. Everest’s marketed portfolio continued to gain momentum NEFECON(R) maintained strong sales momentum. In the first half of 2026, sales revenue from NEFECON(R) reached RMB 889 million, with net sales increasing 94% year-on-year. Through deeper penetration across key hospitals, broader market expansion, enhanced physician and patient education, and continued generation of real-world evidence, Everest is supporting broader adoption of treatment strategies focused on addressing underlying causes, early intervention, and long-term management. Following approval, VELSIPITY(R) moved rapidly into commercialization, with local manufacturing progressing. XERAVA(R) delivered steady hospital sales growth, while local manufacturing advanced as planned. The company also reached an understanding with Hainan Herui Pharmaceutical Co., Ltd. regarding certain NEFECON(R)-related patent matters and entered into a commercialization collaboration for budesonide enteric capsules, further broadening treatment options for patients. Meanwhile, commercialization services for Hasten Biopharmaceuticals continued to contribute to revenue growth. Services for mature products under the CSO arrangement commenced in March 2026, generating RMB 145 million in service revenue and RMB 28 million in commercialization profit in the first half of the year. Mr. Rogers Yongqing Luo, Chief Executive Officer of Everest Medicines, said: “In the first half of 2026, the company continued to execute its strategy and accelerate the translation of innovation into clinical and commercial value. Solid progress across commercialization, BD, in-house R&D, and global expansion further strengthened our foundation for sustainable growth and our ability to bring innovative therapies to patients. Our BD strategy is building a diversified portfolio of future growth drivers through global partnerships for internally developed assets and selective in-licensing of differentiated innovative assets, while our in-house R&D continues to generate clinical progress. With the establishment of a pan-Asia-Pacific commercialization platform, we are also extending our proven capabilities from China into other Asian markets.” EVER001 global licensing deal expected to accelerate overseas development In June, the company entered into an exclusive licensing and collaboration agreement with Travere Therapeutics, Inc. (NASDAQ: TVTX) for the development and commercialization of civorebrutinib (also known as EVER001) in all markets outside China and certain countries in East and Southeast Asia. The deal has a total potential value of up to $1.1425 billion, including an upfront payment of $112.5 million and up to approximately $1.03 billion in additional cash payments tied to specified clinical development, regulatory and commercial milestones across up to five indications. Travere will also pay tiered royalties on future sales in its licensed territories, ranging from high single-digit to double-digit percentages based on annual net sales thresholds. CICC believes the partnership is expected to accelerate the global clinical development and commercialization of EVER001 and could advance its development in membranous nephropathy. BOCOM International is positive on EVER001’s overseas market potential and its development opportunities across additional indications. EVER001 achieved positive 52-week Phase 1b/2a clinical results, and a Phase 2 basket trial has been initiated in China to further evaluate its potential in autoimmune kidney diseases, including FSGS, MCD, and IgAN. BD expansion further strengthens the product pipeline The company continued to selectively introduce mid- to late-stage assets with strong commercial potential. MT1013, DMX-200, and Bejescin(R) strengthened its nephrology and autoimmune portfolio; CARDAMYST(R) and Sumecigrel (formerly known as Vicagrel) further expanded its cardiovascular portfolio; and LNZ100, together with VIS-101, enhanced its ophthalmology portfolio. With multiple assets moving through key regulatory and commercialization milestones, the company is building a diversified portfolio of future growth drivers. CARDAMYST(R) is expected to receive approval in the third quarter of 2026, LEROCHOL(R) and LNZ100 are expected to receive approval in 2027, and MT1013 is expected to receive approval in 2028. In-house R&D and pan-Asia-Pacific expansion advance The company’s in-house R&D also translated into clinical progress. The company’s proprietary AI+mRNA platform also advanced, with its personalized mRNA cancer vaccine EVM16 achieving its first-in-human clinical data readout and planned to enter an investigator-initiated Phase 1b study in the fourth quarter of 2026. EVM18, the company’s in vivo CAR-T therapy, has initiated IIT studies across multiple autoimmune diseases and is advancing toward global IND filings. The acquisition of Hasten Biopharmaceuticals (SG) Pte. Ltd. further strengthened the company’s global commercialization capabilities and established a pan-Asia-Pacific commercialization platform. The platform provides a foundation for scaling the company’s proven commercialization capabilities from China across Asian markets, supporting the regional expansion of both existing and future products. Meanwhile, CBC Group and the company’s Directors have collectively purchased 5.163 million shares since December 2025, with the transactions totaling more than HK$172.5 million, demonstrating their confidence in the company’s strategic direction and long-term prospects. Overall, Everest Medicines is gradually developing a growth model built on the commercialization of core products, portfolio expansion through BD, a pipeline of innovative assets generated through in-house R&D, and international expansion through global partnerships and its pan-Asia-Pacific platform. As the company enters its new phase, the coordinated strengthening of its capabilities in innovation resource integration, commercialization, and global development is expected to provide an important foundation for future growth.
- Obagi Medical/C O R R E C T I O N -- Obagi Medical/In the news release, Obagi Medical Introduces New CLENZIderm M.D.® Resurfacing Multi-Acid Peel Pads Designed to Resurface, Clarify, and Visibly Brighten Skin, issued 18-Aug-2026 by Obagi Medical over PR Newswire, we are advised by the company that an edit was made. The complete, corrected...